Trial
NCT03237611
Low Dose Aprepitant for Patients Receiving Carboplatin
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Albert Einstein College of Medicine
Collaborators
Jacobi Medical Center
Condition
Chemotherapy-induced Nausea and Vomiting
Intervention
Aprepitant 125 mg
Why stopped
Expired IRB approval on 2/11/21
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-13